Regenouve FINE 1x1ml

Cross-linked, high-quality, medical-grade hyaluronic acid for use in medium wrinkles.

A filler containing hyaluronic acid with the smallest particle size and a lower degree of cross-linking.

Thanks to its uniform and closed structure, it creates a natural volume effect that lasts for a long time.

Preparation is smooth and pleasant for both the patient and the practitioner.

Indication

• Smoothing of superficial wrinkles,
• Correction of the eye area,
• smoothing of mimic wrinkles.

Injection area

Upper layer of the dermis (dermis)

Durability of the effect

12-18 months

The preparation contains

Hyaluronic acid 24 mg/ml
Low concentration of endotoxins - less than 0.1 EU/g

Package

• 1 syringe x 1 ml of the preparation
• 27G needle
• 30G needle

CONTRAINDICATION

The product is contraindicated:

In patients with severe allergy symptoms or the presence of multiple severe allergies,

- In patients with a history of facial scarring or hypertrophic scarring,

- In patients with known hypersensitivity to any of the product ingredients, especially sodium hyaluronate,

- In patients with porphyria,

- In pregnant or lactating women,

- In young patients under 18 years of age,

- Patients with an active (or previous) autoimmune disease.

Do not use if there is an active disease such as inflammation, infection or tumor at or near the treatment site.

Do not inject into the periorbital area (eyelids, dark circles, crow's feet) or frontal lamina due to risk of ocular ischemia resulting in loss of vision.

Do not inject intravascularly. Introduction of product into the vascular system may result in embolism, vascular occlusion, ischemia, or infarction,

Rare but serious adverse events associated with intravascular injection of soft tissue fillers into the face have been reported, including temporary or permanent visual disturbances, blindness, cerebral ischemia, or cerebral hemorrhage, which may result in stroke, skin necrosis, and damage to underlying structures of the face,

Discontinue the injection immediately if the patient develops any of the following symptoms, including visual changes, signs of stroke, paleness of the skin, or unusual pain during or soon after the procedure.

Patients should receive immediate medical attention and may require intravascular injection.

Do not use in patients with:

History of streptococcal disease (recurrent throat infections, acute rheumatic fever with or without cardiac involvement),

Patients taking substances that affect platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs or high-dose vitamin C, may experience increased bruising or bleeding at the injection sites, as with any injection.

ADVERSE EFFECTS

Patients must be informed of the potential risks and side effects associated with the injection procedure and the use of this product.

Mild bleeding may occur during the injection and disappear spontaneously as soon as the injection is finished. Occasionally, one or more of the following reactions may occur immediately or as a delayed reaction (the list is not exhaustive):

Reactions usually associated with injections, such as redness, erythema, swelling, or pain.

These reactions may last for a week:

• Hematomas in the treated area,
• Swelling in the treated area,
• Sclerosis or nodules in the treated area,

Stains or discoloration in the treated area:

• Weak effect or poor filling effect,
• Allergy to any of the ingredients of the product, especially sodium hyaluronate.

Cases of necrosis, abscesses and granulomas have been described in the literature following sodium injections with hyaluronate.

However, these rare potential risks should be considered.

Patients should be instructed to report any adverse effects that are prolonged:

More than one week report to their physician,

The physician may then prescribe appropriate treatment for the patient,

Any other adverse reactions associated with injection of the product should be reported to the distributor and/or manufacturer.

Patients should be informed of the indications prior to treatment:

The product and its contraindications and possible adverse events,

The treatment must be performed under appropriate aseptic conditions.

The products are intended for professional use.